Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes

13 Oct 2020

Abstract excerpt

Immunotherapies designed to treat neurodegenerative tauopathies that primarily engage extracellular tau may have limited efficacy as tau is primarily intracellular. We generated tau-targeting single-chain variable fragments (scFvs) and intrabodies (iBs) from the phosphorylated tau-specific antibodies CP13 and PHF1 and the pan-tau antibody Tau5. Recombinant adeno-associated virus (rAAV) was utilized to express...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cellular transport and secretion
Share to Neuroinflammation and Neurodegeneration Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33128896
DOI: 10.1016/j.ymthe.2020.10.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative PhenotypesPMID 33128896Read ↗

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.Semantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Fully Human Bifunctional Intrabodies Achieve Graded Reduction of Intracellular Tau and Rescue Survival of <i>MAPT</i> Mutation iPSC-derived NeuronsSemantic proximity Read ↗

AAV-mediated peripheral single chain variable fragments’ administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapySemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Targeting tauopathy with engineered tau-degrading intrabodies.Semantic proximity Read ↗

Single-Domain Antibody-Based Autophagosome-Targeting Chimera for Tau Clearance and Motor Function Restoration in TauopathiesSemantic proximity Read ↗

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.Semantic proximity Read ↗

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defectsSemantic proximity Read ↗

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.Semantic proximity Read ↗

Proteostasis as a fundamental principle of Tau immunotherapySemantic proximity Read ↗

Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.